Eton Pharmaceuticals (ETON) Cash & Equivalents (2019 - 2025)
Eton Pharmaceuticals (ETON) has disclosed Cash & Equivalents for 7 consecutive years, with $25.9 million as the latest value for Q4 2025.
- Quarterly Cash & Equivalents rose 73.69% to $25.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.9 million through Dec 2025, up 73.69% year-over-year, with the annual reading at $25.9 million for FY2025, 73.69% up from the prior year.
- Cash & Equivalents hit $25.9 million in Q4 2025 for Eton Pharmaceuticals, down from $37.1 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $37.1 million in Q3 2025 to a low of $13.4 million in Q3 2022.
- Historically, Cash & Equivalents has averaged $20.3 million across 5 years, with a median of $19.0 million in 2024.
- Biggest five-year swings in Cash & Equivalents: skyrocketed 209.72% in 2021 and later tumbled 41.09% in 2022.
- Year by year, Cash & Equivalents stood at $14.4 million in 2021, then rose by 13.18% to $16.3 million in 2022, then skyrocketed by 31.17% to $21.4 million in 2023, then crashed by 30.17% to $14.9 million in 2024, then soared by 73.69% to $25.9 million in 2025.
- Business Quant data shows Cash & Equivalents for ETON at $25.9 million in Q4 2025, $37.1 million in Q3 2025, and $25.4 million in Q2 2025.